Sanofi’s big week in­cludes a promis­ing PhI­II for an or­phan dis­ease drug, with plans for a pitch to the FDA

The bio­phar­ma R&D food chain is pay­ing off with a plan at Sanofi to pitch reg­u­la­tors on a new drug for an or­phan dis­ease called cold ag­glu­tinin dis­ease.

The phar­ma gi­ant ush­ered out a state­ment Tues­day morn­ing — af­ter it spelled out plans to rad­i­cal­ly re­struc­ture the com­pa­ny, aban­don­ing car­dio and di­a­betes re­search al­to­geth­er — say­ing that their C1s in­hibitor su­tim­limab had cleared the piv­otal study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.